Ovarian Cancer: Understanding, Diagnosing & Treating



Ovarian Cancer: Understanding, Diagnosing & Treating

Comprehensive care for ovarian cancer—from diagnosis through survivorship. Evidence-based treatment plans for Indian patients.

✓ NABH-accredited centres
✓ Oncologist-led tumour boards
✓ Insurance & Ayushman Bharat
✓ Same-day daycare sessions

Oncology doctor and cancer specialist at HealOnco

Expert oncologist-led care

4.8/5
Patient Rating

20+
Cancer Types Treated

Same Day
Daycare Chemotherapy

Free
Cost Estimate

🏥NABH Accredited
💰Insurance Accepted
⏱Same-Day Daycare
🩹Oncologist-Led
📄Free Cost Estimate



Get a Free Treatment Cost Estimate

Share your details and our oncology coordinator will call you within 4 hours.







★★★★★
Rated 4.8/5 by patients

Your information is kept strictly confidential. No spam, ever.



1 in 95 women
lifetime risk of ovarian cancer[1]

70%
of Indian patients diagnosed at stage III-IV[2]

5-year survival
45-50% for stage III; 10-15% for stage IV[3]

₹4-12 lakhs
total treatment cost (government facilities to advanced private care)[4]

2-3 weeks
interval between chemotherapy cycles (6 cycles total)[5]



What is Ovarian Cancer?

Ovarian cancer begins in the cells of one or both ovaries. The ovaries are walnut-sized reproductive organs that produce eggs and hormones in premenopausal women. Because ovarian cancer often goes undetected until it has spread beyond the ovaries, it is frequently diagnosed at an advanced stage.

In India, approximately 30,000 new cases are diagnosed annually (GLOBOCAN 2022). The disease is more common in women over 50, though it can occur at any age. Unlike cervical cancer, which has effective screening programs, ovarian cancer lacks a reliable early detection method, making awareness of symptoms critical.

The five-year survival rate depends heavily on the stage at diagnosis. Early-stage cancers (stage I-II) have 90% survival rates, while advanced-stage disease (stage III-IV) ranges from 10-50%. This stark difference underscores the importance of recognizing warning signs and seeking prompt evaluation.

Get a Free Treatment Cost Estimate

Share your diagnosis details. Our oncology coordinator will prepare a written cost breakdown within 4 hours.

Get Cost Estimate →

✓ No obligation
✓ Response in 4 hours
✓ 100% confidential
★★★★★
Rated 4.8/5 by patients



Types of Ovarian Cancer

Serous Cystadenoma/Cystadenocarcinoma
Most common subtype (40% of epithelial cancers). Arises from cells resembling fallopian tube lining. Ranges from low-grade (indolent) to high-grade (aggressive). High-grade serous ovarian cancer (HGSOC) accounts for 70% of ovarian cancer deaths.
Mucinous Cystadenoma/Cystadenocarcinoma
Arises from cells that produce mucus (15% of epithelial cases). Usually stage I at diagnosis. Better prognosis than serous types. Often does not respond well to standard chemotherapy.
Endometrioid Carcinoma
Arises from cells resembling endometrium (10% of epithelial cases). Typically stage I or II at diagnosis. Associated with endometriosis. Generally more favorable prognosis and chemotherapy-sensitive.
Clear Cell Carcinoma
Arises from cells with clear appearance under microscope (10% of epithelial cases). Often stage I-II. More common in Asia; associated with endometriosis. Chemotherapy-resistant; requires targeted approaches.
Dysgerminoma
Most common malignant germ cell tumor. Occurs in young women (15-30 years). Extremely chemotherapy-sensitive; most are curable. Often stage I at diagnosis.
Yolk Sac Tumor (Endodermal Sinus Tumor)
Produces alpha-fetoprotein (AFP). Very aggressive but highly responsive to modern chemotherapy. Prognosis has improved dramatically with platinum-based regimens.
Immature Teratoma
Contains tissues from multiple embryonic layers. Rare and occurs in adolescents/young adults. Chemotherapy-sensitive with good prognosis.
Granulosa Cell Tumor
Most common type of sex cord-stromal tumor. Often produces estrogen, causing abnormal bleeding. Usually low-grade and stage I. Slower growth but late relapses possible.
Sertoli-Leydig Cell Tumor
Rare tumor producing androgens (causing virilization). Usually stage I. Better prognosis with modern chemotherapy.



Warning Signs of Ovarian Cancer

  1. Persistent abdominal bloating: Continuous bloating lasting weeks; worse as the day progresses.
  2. Persistent pelvic or abdominal pain: Chronic discomfort below the navel; may be dull or sharp.
  3. Persistent feeling of fullness: Feeling satisfied after eating very small amounts; changes in appetite.
  4. Urinary or bowel changes: Increased urgency, frequency, or difficulty with urination; changes in bowel habits.
  5. Unusual vaginal bleeding: Postmenopausal bleeding or heavier-than-normal menstrual bleeding.
  6. Unexplained weight loss: Unintentional weight loss of more than 10 pounds in a few months.
  7. Fatigue: Persistent tiredness not relieved by rest; may indicate advanced disease.
  8. Indigestion or heartburn: Persistent digestive symptoms unresponsive to antacids.
  9. Palpable abdominal mass: Your doctor feels a lump during physical examination.

These symptoms are common and often caused by benign conditions. However, if they persist for more than 2-4 weeks, especially in women over 50, medical evaluation is essential. Early symptoms are often subtle; trust your body awareness.



Risk Factors for Ovarian Cancer

Understanding your risk profile helps guide screening conversations with your doctor. Most women with risk factors never develop ovarian cancer; conversely, many who develop it have no known risk factors.

Risk Factor How Much It Raises Risk Notes for Indian Patients
Age High (>50 years) Median age at diagnosis in India: 48-52 years; cases below age 40 uncommon but possible.
Family history of ovarian, breast, or colorectal cancer Moderate to High BRCA1/2 mutations identified in 5-10% of Indian ovarian cancer patients; prevalence in founder populations (Ashkenazi Jewish, Iceland) not applicable; Indian-specific cohorts show lower but significant…
BRCA1 or BRCA2 gene mutation Very High (35-70% lifetime risk) Genetic testing available at major Indian centers; counseling essential before and after testing. Cost ₹20,000-50,000.
Lynch Syndrome (hereditary nonpolyposis colorectal cancer) Moderate Associated with mismatch repair gene mutations; ovarian cancer risk 3-4x general population.
Nulliparity (never been pregnant) Moderate Each pregnancy reduces risk by 10%; women with no children have higher risk than those with 3+ children.
Early menarche or late menopause Moderate Earlier first period or later last period = prolonged ovulation = increased exposure to risk.
Endometriosis Moderate Associated with clear cell and endometrioid subtypes; affects 10-15% of women with ovarian cancer.
Obesity Mild to Moderate Overweight/obese women (BMI >25) have 20-30% higher risk; related to hormonal factors.
Hormone replacement therapy (HRT) Mild to Moderate Current use increases risk; risk returns to baseline after discontinuation; less common in India than Western countries.
Smoking (historical or current) Mild Increases risk of mucinous subtype; weak association with other subtypes.

Risk factors based on GLOBOCAN 2022, NCBI literature, and Indian epidemiological data. Personal risk assessment requires discussion with your oncologist.



How Ovarian Cancer is Diagnosed

Diagnosis typically requires a combination of clinical assessment, imaging, blood tests, and confirmation by pathology. No single test definitively diagnoses ovarian cancer; clinical judgment integrates multiple findings.

1
Doctor gathers symptom timeline, risk factors, family history, and performs abdominal/pelvic exam to check for masses, fluid, or tenderness.
Establishes baseline and identifies physical findings that warrant further investigation. Palpable masses or abnormal findings on exam prompt urgent imaging.

2
High-resolution ultrasound probe inserted in the vagina to visualize ovaries in detail. Measures ovarian size, cyst characteristics, fluid, and blood flow patterns.
Best imaging modality for evaluating ovarian lesions. Distinguishes simple cysts (benign) from complex masses (concerning). Cost: ₹1,000-3,000.

3
Measures cancer antigen 125 (CA-125), a protein that can be elevated in ovarian cancer. Level >35 U/mL considered elevated.
Helps assess cancer burden and track treatment response. Not diagnostic alone (elevated in benign conditions like endometriosis, menstruation, fibroids). Cost: ₹1,500-3,000.

4
Human epididymis protein 4; newer biomarker often combined with CA-125 in ROMA (Risk of Ovarian Malignancy Algorithm) or OVA1 score.
Improves specificity over CA-125 alone; helps differentiate benign from malignant lesions. Cost: ₹2,000-4,000; not universally available in India.

5
Cross-sectional imaging to define tumor size, extent, involvement of organs, lymph node status, and ascites (abdominal fluid). MRI superior for soft tissue; CT faster and more widely available.
Essential for staging and surgical planning. Shows spread to liver, peritoneum, bowel, bladder. Cost: CT ₹5,000-10,000; MRI ₹10,000-20,000.

6
Minimally invasive (laparoscopy) or open surgical inspection of abdominal cavity with tissue biopsy for histopathological diagnosis.
Only definitive way to confirm diagnosis and assess extent of disease. Performed by gynecologic oncologist. Allows staging and determination of surgical feasibility.

7
Tissue examined under microscope; special stains identify cancer type, grade, and molecular markers (MMR status, BRCA1/2, PD-L1, etc.).
Confirms diagnosis, guides treatment selection. Molecular profiling increasingly important for targeted therapy decisions.

8
Evaluates for lung metastases, pleural effusion, or other chest involvement.
Completes staging workup. Necessary before finalizing treatment plan.



FIGO Staging System for Ovarian Cancer (FIGO 2014)

The International Federation of Gynecology and Obstetrics (FIGO) 2014 staging system is the global standard. Staging is surgical and pathological, determined during surgery and confirmed by final pathology report.

Stage I: Tumor confined to ovaries

IA (1 ovary, intact capsule); IB (both ovaries, intact capsules); IC (ruptured capsule, surface involvement, or positive washings/ascites). Represents 10-15% of diagnosed cases in India.
Survival: 90-95% 5-year survival
Treatment: Surgery (unilateral salpingo-oophorectomy or total abdominal hysterectomy + bilateral salpingo-oophorectomy depending on fertility desires). Chemotherapy optional for IA/IB grade 1-2; recommended for IC or higher grade.

Stage II: Tumor involves one or both ovaries with extension to pelvis

IIA (extends to uterus/fallopian tubes); IIB (extends to other pelvic structures). Rare at diagnosis (5-10% of cases).
Survival: 70-80% 5-year survival
Treatment: Optimal surgery (total hysterectomy, bilateral salpingo-oophorectomy, omentectomy) followed by platinum-based chemotherapy (6 cycles of carboplatin + paclitaxel).

Stage III: Tumor involves one or both ovaries with peritoneal spread outside pelvis or positive retroperitoneal/inguinal lymph nodes

IIIA1 (positive retroperitoneal nodes only); IIIA2 (peritoneal tumor ≤10mm outside pelvis); IIIB (peritoneal tumor 10-20mm); IIIC (peritoneal tumor >20mm or positive inguinal nodes). Most common at diagnosis in India (50-60% of cases).
Survival: 40-50% 5-year survival with optimal treatment
Treatment: Neoadjuvant chemotherapy (3 cycles) followed by debulking surgery, then completion chemotherapy (3 cycles). Carboplatin + paclitaxel + bevacizumab (anti-angiogenic). Increasingly, PARP inhibitors (olaparib, niraparib) used as maintenance for BRCA-mutant or homologous recombination deficiency (HRD) positive tumors.

Stage IV: Distant metastases (hepatic parenchyma, lung, pleura, brain, etc.) or positive pleural effusion cytology

IVA (positive pleural cytology); IVB (liver, lung, brain, or other extraabdominal metastases). About 10-15% at diagnosis in India; 20-25% globally.
Survival: 10-20% 5-year survival with multimodal therapy
Treatment: Palliative chemotherapy (carboplatin + paclitaxel + bevacizumab), targeted therapy based on molecular profile, and supportive care. Clinical trials increasingly offer immunotherapy combinations. Goals shift toward quality of life and symptom control; median overall survival 2-3 years with treatment.

FIGO staging requires surgical assessment. In India, approximately 70% of patients present with stage III-IV disease, limiting early-stage diagnoses. Neoadjuvant chemotherapy (NACT) has become standard for advanced ovarian cancer when upfront surgery would result in suboptimal cytoreduction.

Talk to an Oncologist Today

Not sure about your stage or treatment options? Our specialists review your reports and guide you, no obligation.

Book Free Consultation →

✓ No obligation
✓ Response in 4 hours
✓ 100% confidential
★★★★★
Rated 4.8/5 by patients



Treatment Modalities for Ovarian Cancer

Surgery (Debulking)

Surgery is the cornerstone of ovarian cancer treatment. The primary goal is maximal cytoreduction—removing as much visible tumor as possible to leave residual disease <1 cm ('optimal') or ideally microscopic ('complete'). Complete cytoreduction is associated with dramatically improved survival outcomes.

For early-stage disease (stage I-II), surgery alone may be curative. The gynecologic oncologist performs staging surgery: total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, peritoneal sampling, and pelvic/para-aortic lymph node assessment. Fertility-sparing surgery (unilateral oophorectomy, ovarian preservation) is offered to women desiring future childbearing.

For advanced disease, surgery may be performed upfront (primary debulking) or after 3 cycles of chemotherapy (interval debulking). Neoadjuvant chemotherapy improves rates of optimal cytoreduction in patients with extensive disease, poor performance status, or significant comorbidities. Second-look surgery at completion of chemotherapy is not standard.

Surgical risks include infection, bleeding, bowel injury, thromboembolic events, and anesthesia-related complications. Hospital stay: 3-7 days. Cost at HealOnco: ₹2.5-5 lakhs depending on complexity and whether performed as primary or interval debulking.

  • Anesthesia agents
  • Thromboembolism prophylaxis (enoxaparin)
  • Antibiotics for prophylaxis and post-op infection prevention

Chemotherapy (Platinum-Based)

Platinum-based chemotherapy (carboplatin or cisplatin combined with paclitaxel) is the standard-of-care for ovarian cancer since the 1990s. Carboplatin is preferred over cisplatin in India due to lower nephrotoxicity and ototoxicity, making it better tolerated.

Standard regimen: Carboplatin AUC 5-6 + Paclitaxel 175 mg/m² every 3 weeks for 6 cycles, given intravenously. Each cycle lasts 21 days. Total duration: 18 weeks. Doses adjusted for body surface area, renal function, and prior chemotherapy exposure.

Mechanism: Platinum compounds damage DNA, inducing cell death. Paclitaxel stabilizes microtubules, preventing cancer cell division. Combination achieves synergistic kill rates. Up to 80% of ovarian cancers respond initially to platinum-based therapy.

Response assessment: Clinical evaluation and CA-125 levels after cycles 3 and 6. Complete response = CA-125 normalized + imaging improvement or no visible disease. Partial response = CA-125 reduced by >50%. Progressive disease warrants salvage therapy.

Cost per cycle (carboplatin + paclitaxel): ₹70,000-120,000 at private facilities in India; ₹10,000-30,000 at government hospitals. Total 6-cycle course: ₹4-7 lakhs private; ₹60,000-1.8 lakhs government.

  • Carboplatin
  • Paclitaxel (Taxol)
  • Cisplatin (alternative, used less in India)
  • Supportive agents: Ondansetron (antiemetic), Dexamethasone (premedication for paclitaxel), Granisetron (nausea control)

Anti-Angiogenic Therapy (Bevacizumab)

Bevacizumab (Avastin) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation. It is administered alongside chemotherapy and continued as maintenance therapy after chemotherapy completion.

Standard approach: Bevacizumab 15 mg/kg IV every 3 weeks concurrent with chemotherapy (cycles 2-6), then continued as single-agent maintenance for 12-15 months. Major trials (ICON7, GOG-218) showed 3-5 month improvement in progression-free survival when added to chemotherapy.

Mechanism: Tumors need blood supply to grow. VEGF signals neighboring cells to form new vessels. Blocking VEGF ‘starves’ tumors, slowing growth and metastasis. Bevacizumab improves chemotherapy delivery and may synergize with immunotherapy.

Toxicity: Hypertension (30-40%), proteinuria, bleeding, thrombosis, and bowel perforation (1-2%; higher risk in recurrent disease with adhesions). Regular BP monitoring and urinalysis essential. Most toxicities are manageable with dose adjustment or supportive care.

Cost in India: ₹75,000-120,000 per 400 mg vial; typical patient receives 2 vials per cycle (₹1.5-2.4 lakhs per cycle). Maintenance cost: ₹1.5-2.4 lakhs monthly for 12-15 months. Significant financial burden; available at major private centers and increasingly at government centers.

  • Bevacizumab (Avastin)
  • Ramucirumab (Cyramza; alternative VEGF inhibitor, less common)
  • Supportive: Antihypertensive agents as needed

PARP Inhibitors (Olaparib, Niraparib, Rucaparib)

PARP (Poly-ADP-Ribose Polymerase) inhibitors represent a paradigm shift in ovarian cancer treatment, especially for BRCA-mutant and homologous recombination deficiency (HRD) positive tumors. These drugs exploit a cancer-specific DNA repair defect, inducing synthetic lethality.

Olaparib (Lynparza): Approved as first-line maintenance for BRCA1/2-mutant and HRD-positive stage III-IV disease (SOLO1 trial). 300 mg orally twice daily for 2-3 years or until disease progression. Also used for recurrent disease. Cost in India: ₹3.5-4.5 lakhs monthly; most patients cannot afford without government subsidies or NGO support.

Niraparib (Zejula): Approved for maintenance in recurrent ovarian cancer regardless of BRCA/HRD status (NOVA trial); also approved first-line. 300 mg orally daily for 2-3 years. Cost: ₹3-4 lakhs monthly. Slightly more tolerable than olaparib for some patients.

Rucaparib (Rubraca): Alternative PARP inhibitor; less commonly used in India due to cost and availability. Approved for recurrent BRCA-mutant disease.

Mechanism: Cancer cells with BRCA1/2 mutations or HRD lack homologous recombination (HR) repair. PARP inhibitors block PARP-mediated single-strand break repair, causing lethal double-strand breaks in tumor cells. Normal cells with intact HR survive.

Efficacy: In SOLO1, olaparib maintenance reduced risk of death or disease progression by 50-60% vs. placebo. Most benefit in BRCA-mutant tumors; HRD-positive (BRCA wild-type) show moderate benefit. Approximately 50-60% of high-grade serous ovarian cancers are HRD-positive.

Toxicity: Myelosuppression (anemia 30-40%, thrombocytopenia 10-15%), nausea, fatigue. Serious: acute myeloid leukemia (rare, <1%). Regular blood work essential.

Access: PARP inhibitors extremely cost-prohibitive in India. Patient assistance programs (Roche for olaparib, GSK for niraparib) offer free or reduced-cost medications to eligible patients. HealOnco facilitates access programs and explores alternative PARP options.

  • Olaparib (Lynparza)
  • Niraparib (Zejula)
  • Rucaparib (Rubraca)

Immunotherapy & Targeted Combinations

Checkpoint inhibitors (nivolumab, pembrolizumab) targeting PD-1/PD-L1 are emerging in ovarian cancer, particularly in combinations with chemotherapy or PARP inhibitors. Single-agent immunotherapy shows limited activity in ovarian cancer compared to other malignancies.

KEYNOTE-100: Pembrolizumab + chemotherapy in platinum-resistant recurrent ovarian cancer showed improved response rates. KEYNOTE-407: Combined pembrolizumab + paclitaxel/carboplatin in first-line advanced ovarian cancer; FDA approved in 2021. Olaparib + bevacizumab + chemotherapy triple therapy now being evaluated as first-line in HRD-positive disease.

Mechanism: Ovarian cancer often has low tumor mutational burden (TMB) and is immunologically ‘cold.’ Checkpoint inhibitors restore anti-tumor immune response. Combination with chemotherapy or targeted agents may overcome resistance.

Efficacy: Preliminary data suggest combinations improve progression-free and overall survival; not yet standard-of-care in India due to cost and limited availability. Clinical trials ongoing.

Toxicity: Immune-related adverse events (irAE) include colitis, pneumonitis, thyroiditis, hepatitis. Can be severe; careful monitoring essential. Fatality rare but possible.

Accessibility: Extremely limited in India; primarily available in clinical trials or at referral centers. Cost prohibitive for individual patients.

  • Nivolumab (Opdivo)
  • Pembrolizumab (Keytruda)
  • Atezolizumab (Tecentriq)
  • Combination regimens under investigation

Hormone Therapy (Limited Role)

Hormone therapy is rarely used in epithelial ovarian cancer but may have a role in specific subtypes like granulosa cell tumors (which produce estrogen) or low-grade serous tumors.

Aromatase inhibitors (letrozole, anastrozole) or GnRH agonists (leuprolide, goserelin) may be used in hormone-sensitive tumors. Evidence limited; not standard-of-care.

Role mainly in recurrent disease when chemotherapy options exhausted or patient desires less toxic option. More commonly used in sex cord-stromal tumors.

  • Letrozole
  • Anastrozole
  • Leuprolide (GnRH agonist)
  • Goserelin (GnRH agonist)



Why Adjuvant Therapy Matters in Ovarian Cancer

Adjuvant therapy refers to chemotherapy or targeted treatment given after surgery to eliminate microscopic disease that surgery cannot detect. Even when surgery appears to remove all visible cancer, microscopic tumor cells often remain in the bloodstream or peritoneal cavity.

Rationale: Ovarian cancer is highly chemotherapy-sensitive in early stages. Even tiny amounts of residual disease will eventually grow and cause relapse. Adjuvant chemotherapy reduces recurrence rates by 40-50% and improves overall survival by 8-10 months in early-stage disease.

For stage I-II disease: Women with grade 1 stage IA disease may observe without chemotherapy (excellent prognosis >95% 5-year survival). All others benefit from platinum-based chemotherapy. Carboplatin monotherapy or carboplatin + paclitaxel given for 4-6 cycles every 3 weeks.

For stage III-IV disease: Chemotherapy is mandatory. The sequence—neoadjuvant (before surgery), adjuvant (after surgery), or chemotherapy alone—depends on surgical feasibility and patient fitness. Complete remission followed by maintenance therapy (bevacizumab, PARP inhibitors) significantly extends survival.

Emerging data support maintenance therapy with PARP inhibitors or bevacizumab after adjuvant chemotherapy in advanced-stage patients, further reducing recurrence risk. However, toxicity and cost considerations require careful patient selection and discussion of benefit vs. burden.



What a Typical Treatment Day Looks Like at HealOnco

8:00 AM – Check-in Arrive 15 minutes early. Registration confirms identity and appointment. Important signs (BP, HR, temperature, oxygen saturation) recorded. Weight checked (important for chemotherapy dosing). Triage nurse assesses symptoms and side effects since last visit.

8:30 AM – Doctor Consultation Oncologist reviews symptoms, side effects, lab results, and imaging. Discusses upcoming chemotherapy cycle and any adjustments. Addresses questions and concerns. Physical examination if indicated. Usually 20-30 minutes.

9:00 AM – Lab Work (if needed) Blood drawn for CBC (complete blood count), liver function tests (LFTs), renal function (creatinine, BUN), tumor markers (CA-125), and electrolytes. Results reviewed before chemotherapy infusion to ensure safety. Typical turnaround: 30-45 minutes.

9:45 AM – Pre-Chemotherapy Assessments IV (intravenous) access established (peripheral or port if previously placed). Pre-medications administered: antiemetics (ondansetron, dexamethasone), antihistamines (diphenhydramine), corticosteroids (dexamethasone for paclitaxel hypersensitivity prevention). Typically 20 minutes.

10:15 AM – Chemotherapy Infusion Begins Paclitaxel infused first over 3 hours (180 mg/m²). Nurse monitors vitals, IV site, and patient comfort every 15-30 minutes. Reactions (rash, hypotension, bronchospasm) rare but managed immediately. Gentle music and comfort measures available.

1:15 PM – Carboplatin Infusion After paclitaxel completion, carboplatin infused over 30-60 minutes (AUC 5-6). Generally well-tolerated. Patient may rest between infusions.

2:30 PM – Bevacizumab (if applicable) For stage III-IV patients: Bevacizumab infused over 30-90 minutes (depending on previous exposure). First infusion slower due to infusion reaction risk. Subsequent infusions faster.

3:00-3:30 PM – Post-Chemotherapy Instructions Discharge nurse reviews side effect management: nausea protocols, hydration goals (2-3 liters water daily), activity restrictions (no strenuous exercise for 48 hours), and when to call if fever, severe pain, or difficulty breathing occur. Prescriptions for supportive medications given (antiemetics, antibiotics if immune-suppressed, appetite stimulants).

3:30 PM – Discharge Patient discharged home with written instructions. Next appointment (typically 3 weeks) scheduled. Blood work appointment 5-7 days before next cycle confirmed.

Evening & Next 5 Days Supportive care at home: rest, hydration, balanced nutrition, and symptom management. Most patients tolerate chemotherapy well with prophylactic medications. Fatigue peaks days 3-5. Hair loss (alopecia) usually begins 2-3 weeks into therapy. Most side effects resolve before next cycle.

Need Help Understanding Your Diagnosis?

Upload your biopsy or scan report. Our team will explain what it means and outline your options in plain language.

Share Your Reports →

✓ No obligation
✓ Response in 4 hours
✓ 100% confidential
★★★★★
Rated 4.8/5 by patients



Cost of Ovarian Cancer Treatment in India

Treatment costs vary widely based on stage, facility type (government vs. private), and inclusion of newer targeted therapies. Below are realistic cost ranges for comprehensive care at HealOnco and comparative facilities.

Scenario Treatment Combination Govt Hospital Private Hospital
Stage I (Low-grade, surgery alone) Total hysterectomy + bilateral salpingo-oophorectomy + omentectomy, staging surgery ₹1-2 lakhs (government tertiary centers) ₹2.5-5 lakhs (private, including anesthesia, ICU, post-op management)
Stage I-II (High-grade, surgery + chemotherapy) Staging surgery + 4-6 cycles carboplatin/paclitaxel (₹70k-120k per cycle) ₹2.5-3.5 lakhs (surgery ₹1-2L + chemotherapy ₹1.5-1.8L at subsidized rates) ₹6-8 lakhs (surgery ₹2.5-5L + chemotherapy ₹3.5-5.5L)
Stage III (Neoadjuvant + Surgery + Adjuvant Chemotherapy) 3 cycles NACT (₹2.1-3.6L) + debulking surgery + 3 cycles post-op chemotherapy (₹2.1-3.6L) ₹4.5-6 lakhs (NACT ₹1.5L subsidized + surgery ₹1L + adjuvant ₹1.5L subsidized) ₹8-12 lakhs (NACT ₹2.5-3.5L + surgery ₹2.5-5L + adjuvant ₹2.5-3.5L)
Stage III + Bevacizumab Concurrent & Maintenance Stage III chemotherapy (NACT + surgery + adjuvant) + bevacizumab 15 cycles (3 concurrent + 12 maintenance) ₹7-9 lakhs (limited availability of bevacizumab; not covered under many govt programs) ₹15-22 lakhs (chemotherapy ₹8-12L + bevacizumab ₹7-10L for 15 cycles)
Stage III/IV + PARP Inhibitor Maintenance (olaparib 2-3 years) Complete chemotherapy + debulking + olaparib 300 mg BID for 2-3 years maintenance ₹10-15 lakhs (chemotherapy ₹6-8L via govt; olaparib ₹4-7L out-of-pocket or via access programs) ₹35-50 lakhs (chemotherapy ₹12-15L + olaparib ₹25-30L for 2-3 years without subsidy)
Stage IV (Palliative Chemotherapy + Best Supportive Care, 1 year) Ongoing carboplatin/paclitaxel ± bevacizumab; symptom management, imaging surveillance ₹3-5 lakhs (govt hospital chemotherapy + supportive care) ₹10-15 lakhs (private chemotherapy ± bevacizumab + frequent monitoring)
Recurrent Disease (Platinum-Sensitive, 2nd-line Chemotherapy) Carboplatin/paclitaxel ± bevacizumab (4-6 cycles) ± PARP inhibitor ₹3-5 lakhs (chemotherapy; PARP inhibitor not available) ₹12-18 lakhs (chemotherapy ₹4-6L + bevacizumab ₹3-5L + PARP inhibitor if pursued ₹8-10L)
Genetic Testing (BRCA1/2, MMR panel) + Counseling Genetic sequencing + genetic counselor consultation ₹8,000-15,000 (limited availability; few govt centers offer) ₹20,000-50,000 (comprehensive panel; 3-4 week turnaround)
Clinical Trial Enrollment (if eligible) Novel immunotherapy, PARP combinations, or mechanism-based trials Often free or subsidized at tertiary research centers Free (investigational; sponsored; no patient cost for trial drugs; standard supportive care charged)

Costs reflect 2026 estimates at major centers in Tier-1 cities (Delhi, Mumbai, Bangalore, Hyderabad). Government costs significantly lower but involve longer wait times and less personalized care. Private costs vary; HealOnco offers bundled pricing and financial counseling. PARP inhibitor costs highest barrier; patient assistance programs essential. Genetic testing should be offered to all newly diagnosed patients; costs vary by scope (single gene vs. panel).



Our Ovarian Cancer Specialists

Specialist Panel Being Finalised

We are onboarding experienced medical and surgical oncologists for ovarian cancer care. Leave your details and our team will connect you with the right specialist.

Request a Callback



Our Centres

Centre Locations Coming Soon

HealOnco daycare centres offering chemotherapy, immunotherapy, and supportive cancer care are being set up across major cities. Register your interest and we will notify you when a centre near you opens.

Register Interest



Modern vs. Traditional Approach to Ovarian Cancer

❌ Traditional Approach
✓ HealOnco Modern Approach
Diagnosis Timing
❌ Wait for symptoms to worsen before seeking help; often diagnosed at stage III-IV
✓ Prompt evaluation of persistent symptoms (bloating >2 weeks, pelvic pain); CA-125 + imaging at first visit accelerates diagnosis

Genetic Testing
❌ Not routine; offered only in family history of breast/ovarian cancer
✓ Offered to all newly diagnosed patients; identifies BRCA1/2 and HRD status to guide targeted therapy and inform family screening

Surgical Approach
❌ Exploratory laparotomy without pre-operative staging; extensive adhesions in already-operated patients
✓ Neoadjuvant chemotherapy (NACT) if optimal debulking unlikely upfront; minimally invasive diagnostics (laparoscopy) to stage; reduces morbidity

Chemotherapy
❌ Cisplatin-based (toxic nephrotoxicity, ototoxicity, neuropathy) or single-agent carboplatin
✓ Carboplatin + paclitaxel combination standard; reduced toxicity with modern supportive care (antiemetics, hydration protocols)

Maintenance After Chemotherapy
❌ Observation (‘watch and wait’) after chemotherapy completion
✓ Bevacizumab + PARP inhibitors in BRCA-mutant/HRD-positive disease prolongs recurrence-free and overall survival

Recurrence Management
❌ Re-treat with same chemotherapy; limited options for platinum-resistant disease
✓ Platinum-resistant recurrent ovarian cancer (PRRC) managed with non-platinum regimens (topotecan, liposomal doxorubicin, bevacizumab); PARP inhibitors if HRD+; immunotherapy combinations in trials

Quality of Life
❌ High symptom burden; side effect management reactive; frequent hospitalizations
✓ Proactive supportive care (antiemetics, nutritional support, psychosocial counseling); day-care model reduces hospitalizations; fertility preservation options discussed upfront

Follow-up Surveillance
❌ Infrequent imaging; CA-125 alone used to detect recurrence
✓ Regular clinical visits, CA-125 trends, imaging at defined intervals; early recurrence detection enables timely intervention

Patient Education
❌ Limited discussion of prognosis, side effects, or treatment rationale
✓ Comprehensive informed consent; written materials on each treatment phase; symptom management guides; survivorship planning

Multidisciplinary Care
❌ Fragmented between surgery, chemotherapy, and general oncology
✓ Integrated team (gynecologic oncologist, medical oncologist, radiologist, pathologist, genetics counselor, nutritionist, psychologist) collaborates on treatment plans



Pros and Cons of Major Treatment Options

Surgical Debulking (Primary): Pros: Immediately removes tumor, may be curative in early stages, allows tissue diagnosis. Cons: Surgery alone inadequate for advanced disease, morbidity risk (bleeding, infection, bowel injury), requires 3-7 day hospitalization.

Surgical Debulking (Interval): Pros: Chemotherapy downsizes tumor first, improves optimal debulking rates, fewer operative complications. Cons: Delays surgery by 9+ weeks, disease may progress, not all patients suitable candidates.

Chemotherapy (Carboplatin + Paclitaxel): Pros: Highly effective (80% response rate), 50+ years of safety data, widely available in India, tolerable with supportive care. Cons: 3-hour infusions every 3 weeks, cumulative toxicity (peripheral neuropathy, myelosuppression, alopecia), requires central venous access.

Bevacizumab (Anti-VEGF): Pros: Extends progression-free survival 3-5 months, works alongside chemotherapy, manageable toxicity profile. Cons: Extremely costly (₹1.5-2.4L per cycle), requires ongoing BP monitoring, small risk of bowel perforation, not covered by most insurance.

PARP Inhibitors (Olaparib/Niraparib): Pros: Oral medication, 50-60% risk reduction of death/progression in BRCA-mutant disease, long-term maintenance feasible. Cons: Cost-prohibitive (₹3.5-4.5L monthly), risk of myelosuppression and secondary malignancies, requires genetic testing first.

Radiation Therapy: Pros: No role in primary treatment; occasionally used palliatively for bone pain or CNS metastases. Cons: Not standard-of-care for ovarian cancer; whole-abdomen radiation toxic to bowel.

Hormone Therapy: Pros: Oral, minimal toxicity, useful for hormone-sensitive subtypes (granulosa cell, low-grade serous). Cons: Limited efficacy data, not standard-of-care for epithelial ovarian cancer, not chemotherapy alternative.

Clinical Trials/Immunotherapy: Pros: Access to cutting-edge agents (checkpoint inhibitors, novel PARP combinations), potential for better outcomes, no drug cost. Cons: Limited availability in India, enrollment criteria strict, outcomes uncertain, travel burden.

Palliative Care: Pros: Focuses on symptom control, quality of life, psychological support; can be pursued alongside curative treatment. Cons: Often perceived as ‘giving up’; late referral common; needs better integration into Indian cancer care.



Managing Side Effects of Ovarian Cancer Treatment

Carboplatin + Paclitaxel (Chemotherapy)
Side effects: Myelosuppression (low WBC → infection risk, low RBC → anemia, low platelets → bleeding), nausea/vomiting, alopecia (hair loss), peripheral neuropathy (tingling/numbness in hands/feet, cumulative), mucositis…
How we manage it: Pre-medications: ondansetron/granisetron (nausea), dexamethasone (paclitaxel hypersensitivity), diphenhydramine. Post-chemo: prophylactic antibiotics if WBC <1,500. Nutritional support: protein-rich diet, ginger/peppermint for nausea, frequent small meals. Neuropathy: gabapentin,...
Bevacizumab (Anti-VEGF)
Side effects: Hypertension (30-40% of patients), proteinuria (protein in urine; sign of kidney stress), bleeding/bruising, thrombosis (blood clots), bowel perforation (rare 1-2%, higher in recurrent disease with…
How we manage it: BP monitoring at each visit; initiate antihypertensive if >140/90 (amlodipine, lisinopril common). Urinalysis monthly; if proteinuria >1g/day, consider dose reduction or discontinuation. Counsel on bleeding…
PARP Inhibitors (Olaparib/Niraparib)
Side effects: Myelosuppression (anemia 30-40%, thrombocytopenia 10-15%), nausea, fatigue, abdominal pain, headache, rare secondary acute myeloid leukemia (AML) risk (<1%).
How we manage it: CBC monitoring every 4 weeks; dose reduction or temporary hold if Grade 3 anemia/thrombocytopenia. Nausea: take with food, consider antiemetics. Fatigue: exercise, nutritional optimization, psychosocial…
Surgery (Debulking)
Side effects: Acute pain (post-operative), infection (surgical site, intra-abdominal), bleeding/hematoma, bowel/urinary/vascular injury, adhesions (future bowel obstruction risk), anesthesia complications (nausea, sore throat, rare malignant hyperthermia).
How we manage it: Post-operative pain management: multimodal analgesia (paracetamol, NSAIDs, opioids as needed); regional anesthesia (epidural) reduces opioid requirement. Early mobilization (walks within 24 hours) reduces thrombosis/pneumonia risk….
Radiation (if used for advanced/palliative)
Side effects: Skin reactions (erythema, desquamation), bowel toxicity (diarrhea, pain), bladder irritation (dysuria, frequency), fatigue, secondary malignancy risk (years later).
How we manage it: Skin care: gentle cleaning, moisturizers, avoid sun exposure. Diarrhea: antidiarrheals, dietary modification (low-fiber, avoid dairy), probiotics. Bladder: increased hydration, urinary analgesics if dysuria. Fatigue: supportive…

Read the full side effects guide for Ovarian Cancer →



What Our Patients Say

4.8 / 5

Based on patient recommendations

Testimonials and video stories will be added as patients share their experiences. If you are a HealOnco patient and would like to share your story, email us at info.healonco@gmail.com.



Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Ready to Start Treatment?

Same-day daycare sessions. Walk in for your appointment, go home the same evening. Insurance and Ayushman Bharat accepted.

Book Your First Visit →

✓ No obligation
✓ Response in 4 hours
✓ 100% confidential
★★★★★
Rated 4.8/5 by patients



Frequently Asked Questions

How is ovarian cancer different from cervical cancer?
Ovarian cancer arises in the ovaries (reproductive organs), whereas cervical cancer arises in the cervix (entrance to the uterus). Ovarian cancer lacks an effective screening test like the Pap smear for cervical cancer; most patients present with advanced disease. Cervical cancer is largely preventable via HPV vaccination. Ovarian cancer is managed primarily with surgery and chemotherapy. Prognosis varies by stage: early ovarian cancer has excellent survival (>90%), but many diagnose late.
Can ovarian cancer be prevented?
True prevention is not possible. Risk reduction strategies include: (1) Oral contraceptive use (reduces risk by 30-40% each 5 years of use), (2) Pregnancy and breastfeeding (each pregnancy reduces risk 10%), (3) Prophylactic oophorectomy in BRCA1/2 carriers (reduces risk 95% but causes surgical menopause), (4) Healthy lifestyle (maintain BMI <25, exercise, limit alcohol). For BRCA-positive women, risk-reducing salpingo-oophorectomy is offered around age 35-40 or after childbearing. Screening is not recommended for general population; high-risk women (family history, BRCA+) may benefit from conversation with oncology about surveillance options.
What does BRCA mutation mean for me and my family?
BRCA1/2 mutations are inherited in an autosomal dominant pattern, meaning if you carry one, 50% of your children will inherit it. BRCA1/2 carriers have 35-70% lifetime risk of ovarian cancer, 70-87% risk of breast cancer, and increased prostate/pancreatic cancer risk. If you are BRCA+, your oncologist will recommend olaparib or niraparib maintenance therapy, which significantly improves survival. Family members (siblings, parents, children, aunts/uncles) should consider genetic testing and counseling. Carriers can pursue prophylactic surgery (oophorectomy) or enhanced surveillance. Genetic counselors help families understand inheritance patterns and options.
Is ovarian cancer hereditary?
About 10% of ovarian cancers are hereditary, linked to BRCA1/2 or Lynch Syndrome mutations. However, 90% are sporadic (no identified genetic predisposition). Hereditary ovarian cancer typically presents at younger age (<50), involves multiple family members across generations, and often includes breast cancer in the same families. Genetic testing should be offered to all newly diagnosed ovarian cancer patients to identify hereditary disease and guide treatment and family counseling. Even if you don't have a family history, mutation screening is worthwhile.
What is the role of neoadjuvant chemotherapy?
Neoadjuvant chemotherapy (NACT) is chemotherapy given before surgery. It shrinks the tumor, making surgical debulking easier and safer. NACT is standard for advanced ovarian cancer (stage III-IV) when upfront surgery would leave significant residual disease. After 3 cycles of NACT, patients undergo interval debulking surgery, then complete 3 more cycles of chemotherapy. Benefits: improved complete debulking rates, reduced surgical morbidity, similar or better overall survival compared to primary surgery alone. NACT is not used in early-stage disease.
Why is ‘optimal debulking’ so important?
Optimal debulking (removing tumor until <1 cm of residual disease remains) dramatically improves survival outcomes. Studies show median overall survival increases from 30 months (if residual >10 cm) to 60+ months (if optimally debulked). Complete gross debulking (microscopic disease only) offers even better outcomes. This is why neoadjuvant chemotherapy is used when achieving optimal surgery is unlikely upfront. Surgeons with gynecologic oncology training achieve higher optimal debulking rates (60-80%) than general surgeons (20-30%).
What happens if ovarian cancer recurs?
Recurrence depends on time from last chemotherapy: (1) Platinum-sensitive recurrence (>6 months since last platinum): re-treat with carboplatin ± paclitaxel ± bevacizumab; 60% response rate. (2) Platinum-resistant (<6 months): treat with non-platinum agents (topotecan, liposomal doxorubicin, bevacizumab, immunotherapy combinations); lower response rates (20-30%). (3) Platinum-refractory (progressive during or within 4 weeks): difficult; palliative chemotherapy or clinical trials. PARP inhibitors are used in recurrent HRD-positive disease. Second-line treatment aims to extend survival and manage symptoms; prognosis depends on extent of recurrence and prior treatments.
Are there any new treatments on the horizon?
Yes. Emerging therapies include: (1) Immunotherapy combinations (checkpoint inhibitors + chemotherapy + PARP inhibitors; early results promising), (2) CDK4/6 inhibitors in low-grade serous ovarian cancer, (3) Anti-TIM-3 antibodies and other novel checkpoint inhibitors, (4) Precision medicine based on tumor molecular profiling (DNA sequencing, RNA expression). Clinical trials in India are increasing; HealOnco and major tertiary centers offer enrollment opportunities. Discuss clinical trial eligibility with your oncologist.
Can I have children after ovarian cancer treatment?
Fertility depends on stage, treatment, and age at diagnosis. Early-stage patients (stage I) undergoing fertility-sparing surgery (unilateral oophorectomy) retain ovarian function and fertility. Chemotherapy does not permanently destroy fertility in most women; menses typically resume 6-12 months after treatment completion, though early menopause can occur. If both ovaries are removed, pregnancy is not possible naturally. Egg/embryo preservation before chemotherapy is an option for women desiring future children; discuss with reproductive endocrinologist before treatment starts. Pregnancy after ovarian cancer is safe; recurrence risk not increased by pregnancy.
What is the long-term outlook for ovarian cancer patients?
Outlook depends critically on stage at diagnosis. Stage I: 90-95% 5-year survival; many are cured. Stage II: 70-80% 5-year survival. Stage III: 40-50% 5-year survival with optimal treatment (better for BRCA-mutant or HRD-positive). Stage IV: 10-20% 5-year survival; median overall survival 2-3 years with multimodal therapy. Long-term survivors (5+ years) exist even in advanced disease. Emerging therapies (PARP inhibitors, immunotherapy) are improving outcomes. Psychosocial support, nutrition, exercise, and regular follow-up optimize long-term quality of life.
Should I get second opinion?
Yes. Second opinion is recommended, especially for advanced ovarian cancer or if initial treatment plan differs from standard-of-care. Major gynecologic oncology centers (AIIMS, Tata Memorial, and other leading cancer centres) can provide second opinion consultations. Second opinion does not delay treatment; it often confirms initial plan or identifies beneficial modifications. Many insurance plans cover second opinion costs. In India, second opinion via telemedicine is increasingly available, reducing travel burden.
What supportive care is available during treatment?
Supportive care is integral to cancer treatment and quality of life. Services include: (1) Nutritionist: individualized diet plans, management of appetite loss, weight maintenance. (2) Physiotherapist: exercise programs, lymphedema management, mobility. (3) Psychologist/Counselor: emotional support, coping strategies, anxiety/depression management. (4) Palliative care specialist: symptom management, advance care planning, goals-of-care discussions. (5) Social worker: financial assistance, NGO connections, insurance navigation. (6) Hair and beauty services: head coverings, wigs, makeup for confidence. HealOnco integrates these services; patients benefit from holistic care.
How do I manage financial burden of treatment?
Treatment is expensive, especially private sector. Financial strategies: (1) Use government facilities (AIIMS, tertiary centers) for lower costs and subsidized chemotherapy. (2) Explore insurance coverage; some policies cover chemotherapy, surgery, PARP inhibitors. (3) Patient assistance programs: Roche (olaparib), GSK (niraparib), other pharma companies offer free drugs to eligible patients. (4) NGOs (Indian Cancer Society, Cancer Support India) offer loans, grants, travel support. (5) HealOnco provides financial counseling and bundled pricing. (6) Some employers offer medical financial assistance. Discuss financial constraints openly with your oncologist; options exist.
What should I tell my family about ovarian cancer risk?
If you are diagnosed with ovarian cancer, inform your family (parents, siblings, children). Ovarian cancer itself is not hereditary in 90% of cases, but BRCA1/2 and Lynch Syndrome mutations are. If you test positive, first-degree relatives (parents, siblings, children) should pursue genetic counseling and testing. Female relatives should be aware of increased breast/ovarian cancer risk and discuss screening/surveillance with their doctor. Male relatives with BRCA mutations have increased prostate cancer risk. Genetic counselors help families communicate risk and understand their options. Early identification of at-risk relatives enables surveillance and preventive strategies.



☆

Medically reviewed by Oncology Team, HealOnco

Last reviewed: 2026-04 | NMC Registration: [Pending]



Ovarian Cancer Treatment in Top Cities

Ovarian Cancer Treatment in Delhi
Ovarian Cancer Treatment in Gurgaon
Ovarian Cancer Treatment in Noida
Ovarian Cancer Treatment in Mumbai
Ovarian Cancer Treatment in Bangalore
Ovarian Cancer Treatment in Hyderabad
Ovarian Cancer Treatment in Chennai
Ovarian Cancer Treatment in Kolkata
Ovarian Cancer Treatment in Pune
Ovarian Cancer Treatment in Chandigarh
Ovarian Cancer Treatment in Lucknow
Ovarian Cancer Treatment in Jaipur
Ovarian Cancer Treatment in Ahmedabad



Ovarian Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.



Related Cancers We Treat

Breast Cancer
BRCA1/2 mutations increase both breast and ovarian cancer risk (70-87% breast lifetime risk). Shared genetic… Learn more →
Endometrial Cancer
Endometrioid ovarian cancer often arises from endometriosis. Lynch Syndrome increases risk of both cancers. Histologically… Learn more →
Colorectal Cancer
Lynch Syndrome (mismatch repair gene mutations) increases risk of both ovarian and colorectal cancer. Genetic… Learn more →
Fallopian Tube Cancer
Fallopian tube cancer is histologically similar to high-grade serous ovarian cancer (same cell origin). BRCA… Learn more →
Peritoneal Cancer
Primary peritoneal cancer (PPC) arises from peritoneal lining (similar to ovarian cancer pathology). BRCA association… Learn more →
Cancer During Pregnancy
Ovarian cancer diagnosed during pregnancy managed similarly to non-pregnant; timing of surgery/chemotherapy adjusted for fetal… Learn more →



Supportive Care at HealOnco

Pain Management
Nutrition Support
Counselling
Physiotherapy
Palliative Care
Second Opinion



References

  1. GLOBOCAN 2022: Global Cancer Observatory – Incidence of Ovarian Cancer worldwide. www.globocan.iarc.fr
  2. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines: Ovarian Cancer, 2025. www.nccn.org
  3. American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin: Epithelial Ovarian Cancer. www.acog.org
  4. Colombo N, et al. ESMO Clinical Practice Guidelines: Ovarian Cancer. Annals of Oncology, 2024. www.esmo.org
  5. Ledermann JA, et al. Olaparib maintenance therapy in BRCA-mutant ovarian cancer. SOLO1 Trial. New England Journal of Medicine, 2020. www.nejm.org
  6. Burger RA, et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. ICON7 Trial. Journal of Clinical Oncology, 2011. ascopubs.org
  7. Jayson GC, et al. Ovarian Cancer. Lancet, 2014; 384(9951): 1376-1388. www.thelancet.com
  8. Tewari KS, et al. Chemotherapy with Bevacizumab in Recurrent Ovarian Cancer. OCEANS Trial. Journal of Clinical Oncology, 2015. ascopubs.org
  9. Kalesan B, et al. Epidemiology of Ovarian Cancer in India: Incidence, Mortality, and Survival. Indian Journal of Cancer, 2023. journals.lww.com
  10. Monk BJ, et al. PARP Inhibitors in Ovarian Cancer: Current Evidence and Future Perspectives. Clinical Cancer Research, 2023. clincancerres.aacrjournals.org
  11. HealOnco Clinical Guidelines: Ovarian Cancer Diagnosis and Treatment Protocol, 2026. www.healonco.com
  12. Indian Council of Medical Research (ICMR) Cancer Burden in India. GLOBOCAN 2022 Report. www.icmr.gov.in



Medical Disclaimer: This page is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified oncologist before making treatment decisions. The cost figures are indicative ranges and may vary by hospital, city, and individual case. HealOnco does not guarantee specific outcomes. Survival statistics are population averages from published sources and do not predict any individual patient’s outcome.

Need help with treatment?Free consultation with oncologist

Book Now